Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCEH1 | Q6PIU2 | 4/20 | 0.37 |
| ▸ | LIPE | Q05469 | 2/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26985713 | 1.00 | NCEH1 (0.37) | NCEH1LIPEUCHL1RAB9AUSP30 | |
| SCHEMBL29175545 | 0.84 | UCHL1 (0.34) | UCHL1DGAT1 | |
| SCHEMBL29977339 | 0.77 | UCHL1 (0.35) | UCHL1 | |
| SCHEMBL24667027 | 0.77 | UCHL1 (0.35) | UCHL1 | |
| SCHEMBL29694349 | 0.74 | UCHL1 (0.39) | LIPEUCHL1USP30DGAT1TSHR | |
| SCHEMBL24568269 | 0.74 | UCHL1 (0.39) | LIPEUCHL1USP30DGAT1TSHR | |
| SCHEMBL21828010 | 0.73 | USP30 (0.43) | UCHL1USP30DGAT1 | |
| SCHEMBL29843363 | 0.73 | USP30 (0.43) | UCHL1USP30DGAT1 | |
| SCHEMBL30746462 | 0.71 | NCEH1 (0.51) | NCEH1RAB9APKMNPC1TSHR | |
| SCHEMBL26984854 | 0.71 | NCEH1 (0.51) | NCEH1RAB9APKMNPC1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001845-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4551558-A2 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | Nested Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024010925-A2 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001845-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | MAPK6, MAPK3, MAPK1 | NCEH1 366/4885LIPE 4254/4885UCHL1 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.